Protara Therapeutics Inc. (NASDAQ:TARA) finished Wednesday with a subtraction of -$0.16 to close at $7.39, a downside of -2.12 percent. An average of 2,603,700 shares of common stock have been traded in the last five days. There was a gain of $0.99 in the past week. The last 20 days have seen an average of 806,395 shares traded, while the 50-day average volume stands at 375,212.
TARA stock has increased by 3.94% in the last month. The company shares reached their 1-month lowest point of $6.18 on 10/06/21. With the stock rallying to its 52-week high on 01/04/21, shares of the company touched a low of $6.18 and a high of $27.51 in 52 weeks. In spite of this, the price is down -73.13% from the 52-week high.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Protara Therapeutics Inc. (TARA) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.30 for the sector. The stock’s beta is 0.80. Other valuation ratios to consider include the price-to-book (PB) ratio at 0.47.
The quick ratio of Protara Therapeutics Inc. for the three months ended June 29 was 23.90, and the current ratio was 23.90, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.00 and a total debt to equity ratio of 0.00 for the quarter ending June 29.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Protara Therapeutics Inc.’s return on assets was -22.00%. For the broader industry, ROE averaged -68.79 over the past year.
For the three-month period that ended June 29, Protara Therapeutics Inc. had $37.83 million in cash. The analyst consensus anticipated Protara Therapeutics Inc.’s latest quarter earnings to come in at -$1.05 per share, but it turned out to be -$1.14, a -8.60% surprise. Shareholders own equity worth $11.24 million.
From a technical analysis perspective, let’s take a brief look at Protara Therapeutics Inc. (TARA) price momentum. RSI 9-day as of the close on 13 October was 58.86%, suggesting the stock is Neutral, with historical volatility in this time frame at 76.29%.
As of today, TARA’s price is $6.97 +15.47% or $0.99 from its 5-day moving average. TARA is currently trading +4.08% higher than its 20-day SMA and -20.54% lower than its 100-day SMA. However, the stock’s current price level is -5.26% below the SMA50 and -70.59% below the SMA200.
The stochastic %K and %D were 60.17% and 43.77%, respectively, and the average true range (ATR) was 0.55. With the 14-day stochastic at 68.36% and the average true range at 0.52, the RSI (14) stands at 54.11%. The stock has reached 0.41 on the 9-day MACD Oscillator while the 14-day reading was at 0.30.
H.C. Wainwright launched coverage on Protara Therapeutics Inc. (NASDAQ: TARA) in its analyst report released on June 04, 2021. The firm assigned the stock a a Buy rating.The consensus rating for Protara Therapeutics Inc. (TARA) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell TARA, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 4 others rate it as a “buy”.
What is TARA’s price target for the next 12 months?
Analysts predict a range of price targets between $32.00 and $50.00, with a median target of $39.00. Taking a look at these predictions, the average price target given by analysts for Protara Therapeutics Inc. (TARA) stock is $40.00.